In particular, trichostatin A (TSA), a histone deacetylase inhibitor that targets ATAD5, has shown promise in reducing chronic inflammation and fibrosis in other disorders such as inflammatory bowel disease and hepatic ischemia-reperfusion damage (45, 46). Here, ATAD5 is linked to inflammatory bowel disease.